Evidence map›Paper›PMID 40856691›Full record

ArticleeLife2025

Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration.

Katerina Rademacher, Zak Doric, Dominik Haddad, Aphroditi Mamaligas, Szu-Chi Liao, Rose Creed, Kohei Kano, Zac Chatterton, Yuhong Fu, Joseph H Garcia and 7 more

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Katerina Rademacher *Gladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, United States.ORCID https://orcid.org/0000-0001-9676-6673
Zak Doric *Gladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, United States.ORCID https://orcid.org/0000-0003-2608-4196
Dominik Haddad *Gladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, United States.ORCID https://orcid.org/0009-0001-9354-7747
Aphroditi MamaligasGladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, United States.ORCID https://orcid.org/0000-0002-9733-6285
Szu-Chi LiaoGladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, United States.ORCID https://orcid.org/0000-0003-2744-363X
Rose CreedAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, United States.ORCID https://orcid.org/0000-0003-4893-2010
Kohei KanoGladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, United States.ORCID https://orcid.org/0000-0002-0223-5781
Zac ChattertonAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, United States.ORCID https://orcid.org/0000-0002-6683-1400
Yuhong FuAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, United States.ORCID https://orcid.org/0000-0003-4539-2039
Joseph H GarciaGladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, United States.ORCID https://orcid.org/0000-0002-7127-9534
Victoria M VanceGladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, United States.ORCID https://orcid.org/0000-0003-4546-5445
Yoshitaka J SeiGladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, United States.ORCID https://orcid.org/0000-0002-4725-8725
Anatol KreitzerGladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, United States.ORCID https://orcid.org/0000-0001-7423-2398
Glenda HallidayAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, United States.ORCID https://orcid.org/0000-0003-0422-8398
Alexandra B NelsonGraduate Program in Neuroscience, University of California San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-9305-5662
Elyssa MargolisGraduate Program in Neuroscience, University of California San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0001-8777-302X
Ken NakamuraGladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, United States.ORCID https://orcid.org/0000-0002-9192-182X

Funding

Understand and probing disrupted glucose metabolism in Alzheimer's diseaseRF1AG064170 · NIA · J. DAVID GLADSTONE INSTITUTES · PI CHAUMEIL, MYRIAM MARIANNE, NAKAMURA, KEN · 2019 to 2019
$3.6M
Determining how neural activity impairs bioenergetics in PD pathogenesisR01NS091902 · NINDS · J. DAVID GLADSTONE INSTITUTES · PI NAKAMURA, KEN · 2015 to 2019
$2.1M
Heterogeneity of Ventral Tegmental Area Neurons and Opioid RewardR01DA030529 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARGOLIS, ELYSSA · 2011 to 2015
$1.8M
Elucidating the Role of Neural Activity in Midbrain Dopamine Neuron DegenerationF31NS137765 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katerina Rademacher · 2024 to 2026
$132k
Aligning Science Across Parkinson's ASAP-020529NIA NIH HHS RF1 AG064170NIDA NIH HHS R01 DA030529NIH HHS F31NS137765NIH HHS R01DA030529NIH HHS RF1AG064170NIH HHS RO1NS091902NINDS NIH HHS F31 NS137765NINDS NIH HHS R01 NS091902Wellcome Trust
6 · The paper itself

Abstract

Parkinson's disease (PD) is characterized by the death of substantia nigra pars compacta (SNc) dopamine (DA) neurons, but the pathophysiological mechanisms that precede and drive their death remain unknown. The activity of DA neurons is likely altered in PD, but we understand little about if or how chronic changes in activity may contribute to degeneration. To address this question, we developed a chemogenetic (DREADD) mouse model to chronically increase DA neuron activity and confirmed this increase using ex vivo electrophysiology. Chronic hyperactivation of DA neurons resulted in prolonged increases in locomotor activity during the light cycle and decreases during the dark cycle, consistent with chronic changes in DA release and circadian disturbances. We also observed early, preferential degeneration of SNc projections, recapitulating the PD hallmarks of selective vulnerability of SNc axons and the comparative resilience of ventral tegmental area axons. This was followed by the eventual loss of midbrain DA neurons. Continuous DREADD activation resulted in a sustained increase in baseline calcium levels, supporting a role for increased calcium in the neurodegeneration process. Finally, spatial transcriptomics from DREADD mice examining midbrain DA neurons and striatal targets, and cross-validation with human patient samples, provided insights into potential mechanisms of hyperactivity-induced toxicity and PD. Our results thus reveal the preferential vulnerability of SNc DA neurons to increased neural activity and support a potential role for increased neural activity in driving degeneration in PD.

Indexed as

Dopaminergic NeuronsMesencephalonNerve DegenerationParkinson DiseaseAnimalsDisease Models, AnimalDopamineHumansMaleMiceMice, Inbred C57BLDopaminedopamine neuronDREADDmouseneural activityneurodegenerationneuroscienceParkinson's disease

Identifiers

PMID40856691
PMCPMC12380431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.